ALK and non-small cell lung carcinoma: Weickhardt and colleagues conducted a retrospective observational study to evaluate the benefits of LAT (radiotherapy or surgery) to oligoprogressive sites and the continuation of crizotinib or erlotinib in patients with metastatic ALK-rearranged (n = 15) or EGFR-mutant (n = 10) NSCLC, respectively.